NCT07485504 2026-03-20
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Phase 1 Not yet recruiting
Clinical Trials
8 trialsNCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07294300 2025-12-19
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06225050 2025-12-03
HAPLO2022
Miltenyi Biomedicine GmbH
Phase NA Not yet recruiting
NCT07255898 2025-12-01
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT06333509 2024-03-27
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Not yet recruiting
NCT06211751 2024-01-18
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Not yet recruiting